Search Result

Isoforms Recommended:	CDK2

Results for "

CDK 2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CDK (146) AAK1 (1) Akt (2) Anaplastic lymphoma kinase (ALK) (1) Angiotensin-converting Enzyme (ACE) (1) Apoptosis (37) ATM/ATR (1) Aurora Kinase (2) Autophagy (6) Bacterial (1) Bcl-2 Family (1) c-Kit (1) Calcium Channel (1) Carbonic Anhydrase (4) Casein Kinase (1) Caspase (1) CFTR (1) Checkpoint Kinase (Chk) (2) Cholinesterase (ChE) (1) COX (1) Cyclin G-associated Kinase (GAK) (1) DNA/RNA Synthesis (1) E3 Ligase Ligand-Linker Conjugates (1) EGFR (10) Endogenous Metabolite (1) Enterovirus (1) ERK (2) FGFR (1) FLT3 (5) GSK-3 (15) HDAC (2) HIV (2) IKK (1) JAK (6) JNK (2) Ligands for Target Protein for PROTAC (1) LIM Kinase (LIMK) (1) MAPKAPK2 (MK2) (2) MDM-2/p53 (1) MEK (2) Microtubule/Tubulin (1) Molecular Glues (3) mTOR (2) Necroptosis (1) Parasite (1) Phosphatase (1) PI3K (4) Pim (1) PKA (1) PKC (3) PKD (1) PROTAC Linkers (1) PROTACs (5) Reactive Oxygen Species (1) Reverse Transcriptase (1) ROS Kinase (1) Salt-inducible Kinase (SIK) (1) Small Interfering RNA (siRNA) (5) SphK (2) Src (2) Topoisomerase (2) Trk Receptor (1) VEGFR (4) Wee1 (1)
By Research Areas:	Cancer (151) Cardiovascular Disease (2) Infection (3) Inflammation/Immunology (7) Metabolic Disease (3) Neurological Disease (9)
Click Chemistry:	Alkynes (1)

173

Inhibitors & Agonists

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Targets Recommended: CDK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15339

CVT-313 4 Publications Verification CDK2 Inhibitor III	CDK	Cancer
CVT-313 (Cdk2 Inhibitor III) is a potent, selective, reversible, and ATP-competitive inhibitor of *CDK2* with IC₅₀ of 0.5 μM. CVT-313 inhibits CDC5L phosphorylation .

HY-RS02374

CDK2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CDK2 Human Pre-designed siRNA Set A contains three designed siRNAs for CDK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CDK2 Human Pre-designed siRNA Set A CDK2 Human Pre-designed siRNA Set A

HY-RS02375

Cdk2 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Cdk2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cdk2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cdk2 Mouse Pre-designed siRNA Set A Cdk2 Mouse Pre-designed siRNA Set A

HY-RS02376

Cdk2 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Cdk2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cdk2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cdk2 Rat Pre-designed siRNA Set A Cdk2 Rat Pre-designed siRNA Set A

HY-144810

CDK2-IN-8	CDK	Cancer
CDK2-IN-8 is a potent *CDK2* inhibitor with an IC₅₀ of 1.74 µM. CDK2-IN-8 shows antiproliferative activity. CDK2-IN-8 has the potential for the research of melanoma .

HY-160643

CDK2-IN-27

CDK Cancer

CDK2-IN-27 (compound 1) is a potent CDK2 inhibitor with IC₅₀ values of <10, >10-20 nM for CDK2/cyclin E1, CDK2/cyclin B1, respectively .

CDK2-IN-27	CDK	Cancer
CDK2-IN-27 (compound 1) is a potent *CDK2* inhibitor with IC₅₀ values of <10, >10-20 nM for CDK2/cyclin E1, CDK2/cyclin B1, respectively .

HY-144811

CDK2-IN-9	CDK Apoptosis	Cancer
CDK2-IN-9 is a potent *CDK2* inhibitor with an IC₅₀ of 0.63 µM. CDK2-IN-9 shows antiproliferative activity. CDK2-IN-9 induces apoptosis and cell cycle arrest at S and G2/M phase. CDK2-IN-9 has the potential for the research of melanoma .

HY-162255

CDK2-IN-23	CDK	Cancer
CDK2-IN-23 (Compound 17) is a kinase selective and highly potent *CDK2* inhibitor (IC₅₀ = 0.29 nM). CDK2-IN-23 shows the pharmacodynamic inhibition of CDK2 in CCNE1-amplified mouse models. CDK2-IN-23 can be used for the research of cancer .

HY-W478102

CDK2-IN-13

CDK Cancer

CDK2-IN-13 (Compound 15) is a CDK2 inhibitor with an IC₅₀ of 12 µM. CDK2-IN-13 can be used in research of cancer .
HY-151580

CDK2-IN-14

CDK Cancer

CDK2-IN-14 (compound 4f) is a highly selective CDK2 inhibitor. CDK2-IN-14 can be used in research of cancer .
HY-148651

CDK2-IN-15

CDK Cardiovascular Disease Cancer

CDK2-IN-15 (Compound 19) is an inhibitor of CDK2 with an IC₅₀ of 2.9 μM. CDK2-IN-15 can be used for cancer research .
HY-139651

CDK2-IN-7

CDK Cancer

CDK2-IN-7 is a CDK2 inhibitor for researching cancer (IC₅₀ < 50 nM).
HY-160556

CDK2-IN-26

CDK Cancer

CDK2-IN-26 (compound 9) is a potent inhibitor of CDK2 .

CDK2-IN-13	CDK	Cancer
CDK2-IN-13 (Compound 15) is a *CDK2* inhibitor with an IC₅₀ of 12 µM. CDK2-IN-13 can be used in research of cancer .

CDK2-IN-14	CDK	Cancer
CDK2-IN-14 (compound 4f) is a highly selective *CDK2* inhibitor. CDK2-IN-14 can be used in research of cancer .

CDK2-IN-15	CDK	Cardiovascular Disease Cancer
CDK2-IN-15 (Compound 19) is an inhibitor of *CDK2* with an IC₅₀ of 2.9 μM. CDK2-IN-15 can be used for cancer research .

CDK2-IN-7	CDK	Cancer
CDK2-IN-7 is a *CDK2* inhibitor for researching cancer (IC₅₀ < 50 nM).

CDK2-IN-26	CDK	Cancer
CDK2-IN-26 (compound 9) is a potent inhibitor of CDK2 .

HY-155441

CDK2-IN-20	CDK	Cancer
CDK2-IN-20 (compound 3b) is an inhibitor of *CDK2. CDK2-IN-20 has cytotoxicity* on tumor cells presenting an IC₅₀ range of 5.52-17.09 µM. CDK2-IN-20 arrests the MCF-7 cell cycle at the S phase and induces apoptosis .

HY-155966

CDK2-IN-19

CDK Cancer

CDK2-IN-19 (Compound 32) is a selective and orally active CDK2 inhibitor (K_i: 0.18 nM). CDK2-IN-19 shows anticancer activity in mice bearing OVCAR3 tumors .

CDK2-IN-19	CDK	Cancer
CDK2-IN-19 (Compound 32) is a selective and orally active *CDK2* inhibitor (K_i: 0.18 nM). CDK2-IN-19 shows anticancer activity in mice bearing OVCAR3 tumors .

HY-150573

CDK2-IN-12	CDK Carbonic Anhydrase	Cancer
CDK2-IN-12 (compound 10b) is a potent *CDK2* inhibitor, with an IC₅₀ of 11.6 μM. CDK2-IN-12 inhibits hCA (carbonic anhydrase) isoforms I, II, IX and XII, with K_I values of 3534, 638.4, 44.3, and 48.8 nM. CDK2-IN-12 shows anticancer activity .

HY-112460

CDK2-IN-3

CDK Cancer

CDK2-IN-3 (compound 3) is a potent and selective CDK2 inhibitor with an ₅₀ of 60 nM .

CDK2-IN-3	CDK	Cancer
CDK2-IN-3 (compound 3) is a potent and selective *CDK2* inhibitor with an ₅₀ of 60 nM .

HY-117535

CDK2-IN-4 2 Publications Verification	CDK	Cancer
CDK2-IN-4 (compound 73) is a potent and selective *CDK2* inhibitor with an IC₅₀ of 44 nM for CDK2/cyclin A, shows 2,000-fold selectivity over CDK1/cyclin B (IC₅₀=86 uM) .

HY-161291

CDK2-IN-25

CDK Cancer

CDK2-IN-25 (compound 7e) is a CDK2 inhibitor with an IC₅₀ of 0.149 μM .
HY-163357

CDK2/MDM2-IN-1

CDK MDM-2/p53 Cancer

CDK2/MDM2-IN-1 (III-13) is a dual inhibitor of CDK2/MDM2 with an IC₅₀ value of 2.60 nM for CDK2. CDK2/MDM2-IN-1 has antitumor activity .

CDK2-IN-25	CDK	Cancer
CDK2-IN-25 (compound 7e) is a CDK2 inhibitor with an IC₅₀ of 0.149 μM .

CDK2/MDM2-IN-1	CDK MDM-2/p53	Cancer
CDK2/MDM2-IN-1 (III-13) is a dual inhibitor of CDK2/MDM2 with an IC₅₀ value of 2.60 nM for CDK2. CDK2/MDM2-IN-1 has antitumor activity .

HY-150572

CDK2-IN-11	CDK Carbonic Anhydrase	Cancer
CDK2-IN-11 (compound 9d) is a potent *CDK2* inhibitor with an IC₅₀ of 6.4 μM, and K_I values of 23.4 nM, 56.3 nM and 44.3 nM for hCA II, hCA IX and hCA XII, respectively. CDK2-IN-11 can be used for researching anticancer .

HY-151580S

CDK2-IN-14-d3

CDK Cancer

CDK2-IN-14-d₃ is a potent and selective CDK2 inhibitor. CDK2-IN-14-d₃ can be used in research of cancer[1].

CDK2-IN-14-d3	CDK	Cancer
CDK2-IN-14-d₃ is a potent and selective CDK2 inhibitor. CDK2-IN-14-d₃ can be used in research of cancer[1].

HY-157516

CDK2-IN-22	CDK	Cancer
CDK2-IN-22 (compound 7I) is a potent *CDK2* inhibitor with an IC₅₀ of 64.42 nM. CDK2-IN-22 presents a broad antiproliferative efficacy toward diverse cancer cells MV4-11, HT-29, MCF-7, and HeLa with IC₅₀ values of 0.83 μM, 2.12 μM, 3.12 μM, and 8.61 μM, respectively .

HY-149436

CDK2/Bcl2-IN-1	CDK	Cancer
CDK2/Bcl2-IN-1 (compound 1), a saponin and a CDK-2 inhibitor (IC₅₀=117.6 nM) with promising cytotoxicity against cancer cells. CDK2/Bcl2-IN-1 also inhibits Bcl-2, and induces apoptosis in A549 lung cancer cells .

HY-148213

CDK2/4/6-IN-1	CDK	Cancer
CDK2/4/6-IN-1(example 29) is a *CDK2/4/6* inhibitor with IC₅₀ values of 2.5, 23.7 and 44.3 nM for CDK2, CDK4 and CDK6, respectively. CDK2/4/6-IN-1 can be used in cancer research . CDK2/4/6-IN-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-P3730

Cdk2/Cyclin Inhibitory Peptide I

CDK Cancer

Cdk2/Cyclin Inhibitory Peptide I (Tat-LFG), a CDK2 inhibitor, kills U2OS osteosarcoma cells in a dose-dependent manner .
HY-P3731

Cdk2/Cyclin Inhibitory Peptide II

CDK Cancer

Cdk2/Cyclin Inhibitory Peptide II (Tat-LDL), a CDK2 inhibitor, kills U2OS osteosarcoma cells in a dose-dependent manner .
HY-162270

CDK2-IN-24

CDK Cancer

CDK2-IN-24 (compound 3f) is an inhibitor of cyclin-dependent kinase 2 with an elevated binding energy value .
HY-148214

CDK2/4/6-IN-2

CDK Cancer

CDK2/4/6-IN-2 is a CKD2/4/6 inhibitor, with IC₅₀ values less than 1 μM, 10 nM, 100 nM respectively .

Cdk2/Cyclin Inhibitory Peptide I	CDK	Cancer
Cdk2/Cyclin Inhibitory Peptide I (Tat-LFG), a *CDK2* inhibitor, kills U2OS osteosarcoma cells in a dose-dependent manner .

Cdk2/Cyclin Inhibitory Peptide II	CDK	Cancer
Cdk2/Cyclin Inhibitory Peptide II (Tat-LDL), a *CDK2* inhibitor, kills U2OS osteosarcoma cells in a dose-dependent manner .

CDK2-IN-24	CDK	Cancer
CDK2-IN-24 (compound 3f) is an inhibitor of cyclin-dependent kinase 2 with an elevated binding energy value .

CDK2/4/6-IN-2	CDK	Cancer
CDK2/4/6-IN-2 is a CKD2/4/6 inhibitor, with IC₅₀ values less than 1 μM, 10 nM, 100 nM respectively .

HY-RS02378

CDK2AP1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CDK2AP1 Human Pre-designed siRNA Set A contains three designed siRNAs for CDK2AP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CDK2AP1 Human Pre-designed siRNA Set A CDK2AP1 Human Pre-designed siRNA Set A

HY-RS02379

CDK2AP2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CDK2AP2 Human Pre-designed siRNA Set A contains three designed siRNAs for CDK2AP2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CDK2AP2 Human Pre-designed siRNA Set A CDK2AP2 Human Pre-designed siRNA Set A

HY-134622

*GSK-3/CDK5/CDK2-IN-1*	CDK GSK-3	Neurological Disease Cancer
GSK-3/CDK5/CDK2-IN-1, an imidazole derivative, is an inhibitor of *cdk5, cdk2, and GSK-3* extracted from patent WO2002010141A1, example 9a. GSK-3/CDK5/CDK2-IN-1 can be used for the research of cancer, and neurodegenerative diseases .

HY-151573

*EGFR/CDK2-IN-1*	EGFR CDK	Cancer
EGFR/CDK2-IN-1 (Compound 3b) is an *EGFR/CDK2* inhibitor. EGFR/CDK2-IN-1 shows good cytotoxicity against MCF7 and HepG2 cells. EGFR/CDK2-IN-1 can be used in cancer research .

HY-156114

*EGFR/CDK2-IN-2*	EGFR CDK	Cancer
EGFR/CDK2-IN-2 (compound 6a) is a dual inhibitor of EGFR and CDK-2 with IC₅₀s of 19.6 and 87.9 nM, respectively. EGFR/CDK2-IN-2 induces apoptosis in MCF-7 cells and arrests the cell cycle in the S phase. EGFR/CDK2-IN-2 has significant anti-cancer cell toxicity and inhibits MCF-7 with an IC₅₀ of 0.39 μM .

HY-156115

*EGFR/CDK2-IN-3*	EGFR CDK	Cancer
EGFR/CDK2-IN-3 (compound 4b) is a dual inhibitor of EGFR and CDK-2 with IC₅₀s of 71.7 and 113.7 nM, respectively. EGFR/CDK2-IN-3 induces apoptosis in MCF-7 cells and arrests the cell cycle in the S phase. EGFR/CDK2-IN-3 has significant anti-cancer cell toxicity and inhibits MCF-7 with an IC₅₀ of 3.16 μM .

HY-156116

*EGFR/CDK2-IN-4*	EGFR CDK	Cancer
EGFR/CDK2-IN-4 (compound 4c) is a dual inhibitor of EGFR and CDK-2 with IC₅₀s of 89.6 and 165.4 nM, respectively. EGFR/CDK2-IN-4 induces apoptosis in MCF-7 cells and arrests the cell cycle in the S phase. EGFR/CDK2-IN-4 has significant anti-cancer cell toxicity and inhibits MCF-7 with an IC₅₀ of 2.74 μM .

HY-143497

*HDAC1/2 and CDK2-IN-1*	HDAC CDK Apoptosis	Cancer
HDAC1/2 and CDK2-IN-1 (compound 14d) is a potent HDAC1, HDAC2 and *CDK2* dual inhibitor, with IC₅₀ values of 70.7, 23.1 and 0.80 μM, respectively. HDAC1/2 and CDK2-IN-1 can block the cell cycle and induce apoptosis. HDAC1/2 and CDK2-IN-1 exhibits desirable in vivo antitumor activity .

HY-130709

*PROTAC CDK2/9 Degrader-1*	PROTACs CDK	Cancer
PROTAC CDK2/9 Degrader-1 (Compound F3) is a potent dual degrader for *CDK2* (DC₅₀=62 nM) and *CDK9* (DC₅₀=33 nM). PROTAC CDK2/9 Degrader-1 suppresses prostate cancer PC-3 cell proliferation (IC₅₀=0.12 µM) by effectively blocking the cell cycle in S and G2/M phases. PROTAC CDK2/9 Degrader-1 is a PROTAC by tethering *CDK* inhibitor with Cereblon ligand .

HY-15569

NU6102	CDK	Cancer
NU6102 is a potent *CDK1* and *CDK2* inhibitor with IC₅₀s of 9.5 nM and 5.4 nM for *CDK1/cyclinB* and *CDK2/cyclinA3, respectively. NU6102 shows selectivity for CDK1/CDK2* over CDK4 (IC₅₀ of 1.6 μM), DYRK1A (IC₅₀ of 0.9 μM), PDK1 (IC₅₀ of 0.8 μM) and ROCKII (IC₅₀ of 0.6 μM) .

HY-18299A

Purvalanol A 2 Publications Verification NG-60	CDK Autophagy Apoptosis	Cancer
Purvalanol A is a potent *CDK* inhibitor, which inhibits cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, cdk4-cyclin D1, and cdk5-p35 with IC₅₀s of 4, 70, 35, 850, 75 nM, resepctively.

HY-112468

PNU112455A hydrochloride	CDK	Cancer
PNU112455A hydrochloride is an ATP-competitive *CDK2* and *CDK5* inhibitor. PNU112455A hydrochloride binds to the ATP site of CDK2 and CDK5 with K_ms of 3.6 and 3.2 μM, respectively .

HY-10329

JNJ-7706621 2 Publications Verification	Aurora Kinase CDK Apoptosis	Cancer
JNJ-7706621 is a potent aurora kinase inhibitor, and also inhibits *CDK1* and *CDK2, with IC₅₀s of 9 nM, 3 nM, 11 nM, and 15 nM for CDK1, CDK2, aurora-A* and aurora-B, respectively .

HY-111356

IIIM-290

CDK Cancer

IIIM-290 is a potent and oral CDK inhibitor with IC₅₀s of 90 and 94 nM for CDK2/A and CDK9/T1.

IIIM-290	CDK	Cancer
IIIM-290 is a potent and oral *CDK* inhibitor with IC₅₀s of 90 and 94 nM for CDK2/A and CDK9/T1.

HY-15004

AUZ 454 4 Publications Verification K03861	CDK	Cancer
AUZ 454 (K03861) is a type II *CDK2* inhibitor with K_d of 8.2 nM. AUZ 454 (K03861) inhibits CDK2 activity by competing with binding of activating cyclins.

HY-130981

FN-1501-propionic acid	CDK Ligands for Target Protein for PROTAC	Cancer
FN-1501-propionic acid is a *CDK2/9* ligand for PROTAC. FN-1501-propionic acid and a CRBN ligand have been used to design PROTAC CDK2/9 degrader (HY-130709) .

HY-11009

CGP60474 5 Publications Verification	CDK PKC	Cancer
CGP60474, a highly potent anti-endotoxemic agent, is a potent cyclin-dependent kinase (CDK) inhibitor (IC₅₀ values are 26, 3, 4, 216, 10, 200 and 13 nM for CDK1/B, CDK2/E, CDK2/A, CDK4/D, CDK5/p25, CDK7/H and CDK9/T, respectively). CGP60474 is a selective and ATP-competitive PKC inhibitor .

HY-111932

Indirubin-5-sulfonate	CDK GSK-3	Cancer
Indirubin-5-sulfonate is a cyclin-dependent kinase (CDK) inhibitor, with IC₅₀ values of 55 nM, 35 nM, 150 nM, 300 nM and 65 nM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E, CDK4/cyclin D1, and CDK5/p35, respectively . Indirubin-5-sulfonate also shows inhibitory activity against GSK-3β .

HY-12843

Bohemine 1 Publications Verification	CDK ERK	Cancer
Bohemine is a purine analogue and is a synthetic and selective *CDK* inhibitor with IC₅₀s of 4.6 μM, 83 μM, and 2.7 μM for Cdk2/cyclin E, Cdk2/cyclin A, and Cdk9/cyclin T1, respectively. Bohemine also inhibits ERK2 with an IC₅₀ of 52 μM and has less inhibitory effect on CDK1, CDK4 and CDK6. Bohemine has a broad spectrum anti-cancer activities .

HY-12529

Ro-3306 30+ Cited Publications	CDK Apoptosis	Cancer
Ro-3306 is a potent and selective inhibitor of *CDK1, with K_is of 20 nM, 35 nM and 340 nM for CDK1, CDK1/cyclin B1 and CDK2*/cyclin E, respectively.

HY-101212

Fadraciclib 5 Publications Verification CYC065	CDK	Cancer
Fadraciclib (CYC065) is a second-generation, orally available ATP-competitive inhibitor of *CDK2/CDK9* kinases with IC₅₀s of 5 and 26 nM, respectively .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N5072

Desmethylglycitein 4',6,7-Trihydroxyisoflavone	Flavonoids Classification of Application Fields Leguminosae Glycine max (L.) merr Source classification Phenols Polyphenols Plants Disease Research Fields Isoflavones Cancer	CDK PI3K PKC
Desmethylglycitein (4',6,7-Trihydroxyisoflavone), a metabolite of daidzein, sourced from Glycine max with antioxidant, and anti-cancer activities. Desmethylglycitein binds directly to *CDK1* and *CDK2* in vivo, resulting in the suppresses CDK1 and CDK2 activity . Desmethylglycitein is a direct inhibitor of protein kinase C (PKC)α, against solar UV (sUV)-induced matrix matrix metalloproteinase 1 (MMP1) . Desmethylglycitein binds to PI3K in an ATP competitive manner in the cytosol, where it inhibits the activity of PI3K and downstream signaling cascades, leading to the suppression of adipogenesis in 3T3-L1 preadipocytes .

HY-149436

CDK2/Bcl2-IN-1	Structural Classification Terpenoids Zygophyllaceae Source classification Diterpenoids Plants Zygophyllum album L.f.	CDK
CDK2/Bcl2-IN-1 (compound 1), a saponin and a CDK-2 inhibitor (IC₅₀=117.6 nM) with promising cytotoxicity against cancer cells. CDK2/Bcl2-IN-1 also inhibits Bcl-2, and induces apoptosis in A549 lung cancer cells .

HY-W019806

Lacto-N-fucopentaose I LNFP I	Infection Structural Classification Natural Products Polysaccharides Classification of Application Fields Animals Inflammation/Immunology Disease Research Fields Saccharides	Endogenous Metabolite CDK Reactive Oxygen Species Apoptosis Enterovirus Bacterial
Lacto-N-fucopentaose I (LNFPI) is a human milk oligosaccharide (HMO), possessing antiviral and antibacterial activity. Lacto-N-fucopentaose I can reduce capsid protein VP1 to block virus adsorption, promote *CDK2* and reduce cyclin E to recover cell cycle S phase block. Lacto-N-fucopentaose I inhibits ROS production and apoptosis in virus-infected cells. Lacto-N-fucopentaose I can also regulate intestinal microbiota to affect immune system development .

Recombinant Proteins Recommended:

Cyclin-Dependent Kinase 2 (CDK2)

Species:	Human (9)
Tag:	His (9) SUMO (1) GST (5) Flag (4)
Source:	HEK293 (1) Sf9 insect cells (5) E. coli (3)

Cat. No.	Compare	Product Name	Species	Source

HY-P70014

	CDK2 Protein, Human (His) rHuCyclin-dependent kinase 2/CDK2, His; Cyclin-Dependent Kinase 2; Cell Division Protein Kinase 2; p33 Protein Kinase; CDK2; CDKN2	Human	E. coli
	CDK2 is an important serine/threonine protein kinase that plays a critical regulatory role in the cell cycle, especially during meiosis. It phosphorylates various substrates (CTNNB1, USP37, p53/TP53, NPM1, CDK7, RB1, BRCA2, MYC, NPAT, EZH2) and coordinates centrosome duplication and initiation of DNA synthesis at the G1-S transition. CDK2 Protein, Human (His) is the recombinant human-derived CDK2 protein, expressed by E. coli , with N-6*His labeled tag. The total length of CDK2 Protein, Human (His) is 298 a.a., with molecular weight of 32-35 kDa.

HY-P70014A

	CDK2 Protein, Human (N-His) rHuCyclin-dependent kinase 2/CDK2, His; Cyclin-Dependent Kinase 2; Cell Division Protein Kinase 2; p33 Protein Kinase; CDK2; CDKN2	Human	E. coli
	CDK2 is an important serine/threonine protein kinase that plays a critical regulatory role in the cell cycle, especially during meiosis. It phosphorylates various substrates (CTNNB1, USP37, p53/TP53, NPM1, CDK7, RB1, BRCA2, MYC, NPAT, EZH2) and coordinates centrosome duplication and initiation of DNA synthesis at the G1-S transition. CDK2 Protein, Human (N-His) is the recombinant human-derived CDK2 protein, expressed by E. coli , with N-6*His labeled tag. The total length of CDK2 Protein, Human (N-His) is 297 a.a., with molecular weight of approximately 32.65 kDa.

HY-P702675

	CDK2-CCNA2 Protein, Human (sf9, GST, His) CDK2; cyclin-dependent kinase 2; p33 protein kinase; cell devision kinase 2; cdc2-related protein kinase; cell division protein kinase 2; p33(CDK2)	Human	Sf9 insect cells

HY-P702676

	CDK2-CCND1 Protein, Human (sf9, GST, Flag, His) CDK2; cyclin-dependent kinase 2; p33 protein kinase; cell devision kinase 2; cdc2-related protein kinase; cell division protein kinase 2; p33(CDK2)	Human	Sf9 insect cells

HY-P702677

	CDK2-CCNE1 Protein, Human (sf9, GST, His, Flag) CDK2; cyclin-dependent kinase 2; p33 protein kinase; cell devision kinase 2; cdc2-related protein kinase; cell division protein kinase 2; p33(CDK2)	Human	Sf9 insect cells

HY-P702678

	CDK2-CCNE2 Protein, Human (sf9, GST, Flag, His) CDK2; cyclin-dependent kinase 2; p33 protein kinase; cell devision kinase 2; cdc2-related protein kinase; cell division protein kinase 2; p33(CDK2)	Human	Sf9 insect cells

HY-P702679

	CDK2-CCNO Protein, Human (sf9, GST, Flag, His) CDK2; cyclin-dependent kinase 2; p33 protein kinase; cell devision kinase 2; cdc2-related protein kinase; cell division protein kinase 2; p33(CDK2)	Human	Sf9 insect cells

HY-P7850

	CDK2AP2 Protein, Human (HEK293, His) rHuCyclin-dependent kinase 2-associated protein 2/CDK2AP2, His; Cyclin-dependent kinase 2-associated protein 2; CDK2-associated protein 2; DOC-1-related protein; DOC-1R; CDK2AP2; DOC1R	Human	HEK293
	CDK2AP2 protein, a vital component of the NuRD complex, actively engages in chromatin remodeling. It inhibits G1/S phase transition by suppressing CDK2, impeding CDK2's interaction with cyclin E or A. Beyond cell cycle control, CDK2AP2 is crucial for ESC self-renewal, ensuring survival during differentiation, and regulates microtubule organization in metaphase II oocytes. Part of the NuRD complex, CDK2AP2 collaborates with proteins like MTA1, MTA2, HDAC1, and others, showcasing its multifaceted regulatory functions. CDK2AP2 Protein, Human (HEK293, His) is the recombinant human-derived CDK2AP2 protein, expressed by HEK293, with C-6*His labeled tag. The total length of CDK2AP2 Protein, Human (HEK293, His) is 126 a.a., with molecular weight of ~26.0 kDa.

HY-P71531

	SKP2 Protein, Human (His-SUMO) CDK2/Cyclin A associated protein p45; Cyclin A/CDK2 associated protein p45; Cyclin-A/CDK2-associated protein p45; F box protein Skp2; F box/LRR repeat protein 1; F-box protein Skp2; F-box/LRR-repeat protein 1; FBL 1; FBL1; FBXL 1; FBXL1; FLB 1; FLB1; MGC1366; p45; p45skp2	Human	E. coli
	SKP2 serves as a substrate recognition component in the SCF E3 ubiquitin-protein ligase complex, directing ubiquitination and proteasomal degradation of key proteins in the cell cycle, signaling, and transcription. It crucially recognizes phosphorylated CDKN1B/p27kip and regulates the G1/S transition. SKP2 Protein, Human (His-SUMO) is the recombinant human-derived SKP2 protein, expressed by E. coli , with N-SUMO, N-6*His labeled tag. The total length of SKP2 Protein, Human (His-SUMO) is 424 a.a., with molecular weight of ~63.8 kDa.

Cat. No.	Product Name	Chemical Structure

HY-151580S

CDK2-IN-14-d3

CDK2-IN-14-d₃ is a potent and selective CDK2 inhibitor. CDK2-IN-14-d₃ can be used in research of cancer[1].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks